Raytheon awarded $71 million in Navy contracts for missile systems
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), a biotech company with a market capitalization of $1.1 billion and an "GREAT" financial health score according to InvestingPro, saw its CEO Peter Greenleaf recently sell shares of the company, according to a recent SEC filing. Greenleaf sold a total of 360,540 shares over two days, with 195,593 shares sold on March 3 at a weighted average price of $8 per share and 164,947 shares sold on March 4 at a weighted average price of $7.92 per share. The transactions totaled approximately $2.87 million. The company’s stock, currently trading at $8.08, has shown strong momentum with a 44% return over the past year.
In addition to these sales, Greenleaf acquired 290,728 shares on February 28 and 333,705 shares on March 3 at no cost, as part of performance awards and grants. Following these transactions, Greenleaf’s direct ownership of Aurinia’s common stock stands at 1,788,945 shares.
These transactions come as part of routine financial management and do not necessarily reflect Greenleaf’s outlook on the company’s future performance.
In other recent news, Aurinia Pharmaceuticals reported its fourth-quarter 2024 earnings, revealing an earnings per share (EPS) of $0.01, which fell short of analysts’ expectations of $0.03. The company’s revenue also came in below forecasts, reaching $59.9 million against a projected $61.7 million. However, total revenue for 2024 showed a significant increase of 34% year-over-year, reaching $235.1 million. Aurinia’s flagship product, LUKINIS, reported net product sales of $216.2 million for the year, marking a 36% increase from 2023. Despite the overall annual growth, the company faced challenges in meeting analysts’ expectations for the fourth quarter.
Aurinia Pharmaceuticals has set a total revenue guidance of $250 million to $260 million for 2025, with net product sales expected to range from $240 million to $250 million. The company is advancing its pipeline, particularly with AUR200, and is preparing for potential generic competition. CEO Peter Greenleaf emphasized the company’s commitment to defending its intellectual property rights for LUKINIS. Additionally, the company remains focused on expanding its market presence and product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.